Antibody

21개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved21 programs
AntibodyCurated CoreFDAAbbVieApproved

risankizumab-rzaa (Skyrizi, BI 655066, risankizumab)

Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 110Status Approved
AntibodyCurated CoreRochePhase 2

Avastin (Avastin)

Neovascular Age-Related Macular Degeneration · Extranodal NK/T-cell Lymphoma, Nasal Typ

#ExtranodalNKT-cellLymphomaNasalT#Antibody#Phase2#BioJungboMoa-pick#Popular+3
Trials 1444Status Active
AntibodyCurated CoreJanssenApproved

Remicade® (Remicade®)

Crohn's Disease · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Approved#BioJungboMoa-pick#Popular+3
Trials 406Status Active
AntibodyLimited DatastaleNovartisApproved

Basiliximab (Basiliximab)

Type 1 Diabetes Mellitus · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#Antibody#Approved#Popular#monoclonal-antibody+2
Trials 58Status Active
AntibodyLimited DatastaleUniversity of CalgaryApproved

Anti-IL12/23 or anti-IL23 - Risankizumab (Anti-IL12/23 or anti-IL23 - Risankizumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#University
Trials 3Status Recruiting
AntibodyLimited DatastalePeking UniversityPhase 2

Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (Dexamethasone, azacytidine, Pegaspargase, Tislelizumab)

NK/T Cell Lymphoma · NK/T Cell Lymphoma

#NKTCellLymphoma#Antibody#Phase2#monoclonal-antibody#NK+2
Trials 2Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryPeripheralTC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHanyang University Seoul Hospit…Approved

Biological: Etanercept and its biosimilars (Biological: Etanercept and its biosimilars)

Ankylosing Spondylitis; Axial Spondyloarthritis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Approved#monoclonal-antibody#AxialSpondyloarthritis+1
Trials 1Status Active
AntibodyLimited DatastaleEssen BiotechPhase 2

pembrolizumab (Keytruda, EBNK-001 + IL-15 + Pembrolizumab)

Cancer; Sarcoma · Cancer

#Cancer#Antibody#Phase2#monoclonal-antibody#Sarcoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleInstitut für Klinische Krebsfor…Phase 3

trastuzumab (Herceptin, FLOT + Herceptin/Pertuzumab)

Stomach Cancer; Gastroesophageal Junction Cancer · Stomach Cancer

#StomachCancer#Antibody#Phase3#monoclonal-antibody#GastroesophagealJunctionCancer+1
Trials 1Status Active
AntibodyLimited DatastaleAbbViePhase 3

adalimumab biosimilar (GP2017, GP2017 (adalimumab biosimilar))

Ankylosing Spondylitis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleIstituto Clinico HumanitasPhase 2

anti-NKG2A monoclonal antibody (Monalizumab, Monalizumab (anti-NKG2A monoclonal antibody))

Acute Myeloid Leukaemia; MDS (Myelodysplastic Syndrome) · Acute Myeloid Leukaemia

#AcuteMyeloidLeukaemia#Antibody#Phase2#monoclonal-antibody#MDSMyelodysplasticSyndrome+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
AntibodyLimited DatastaleAbbVieApproved

infliximab, adalimumab, etanercept (TNF blockers, TNF blockers (infliximab, adalimumab, etanercept))

Arthritis, Rheumatoid; Spondylitis, Ankylosing · Arthritis, Rheumatoid

#ArthritisRheumatoid#Antibody#Approved#monoclonal-antibody#Arthritis+3
Trials 1Status Active
AntibodyLimited DatastaleMediLink Therapeutics (Suzhou) …Phase 2

pembrolizumab (Keytruda, YL242; Pembrolizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#MediLink
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →